10/6/2022 8:51:57 AM
DURECT Reaches Enrollment Milestone In Phase 2b AHFIRM Trial; Enrollment Completion Now Anticipated In Q2 2023
9/26/2022 8:32:25 AM
Innocoll : POSIMIR Commercially Available In U.S. For Treatment Of Post-surgical Pain In Adults
7/5/2022 8:32:28 AM
DURECT Appoints Timothy Papp As CFO
3/7/2022 4:13:24 PM
DURECT Q4 Loss/share $0.03 Vs. Profit $0.02 Year Ago
3/1/2022 8:43:51 AM
DURECT Doses First European Patient In Phase 2b AHFIRM Study Of Larsucosterol In Severe Alcohol-Associated Hepatitis
12/22/2021 7:33:00 AM
DURECT, Innocoll Announce $136 Mln U.S. Licensing Agreement For POSIMIR
11/10/2021 9:04:07 AM
DURECT Doses First Ex-U.S. Patient In Phase 2b Study Of Larsucosterol In Severe Alcohol-Associated Hepatitis
6/23/2021 9:10:17 AM
DURECT Presents Addl Clinical Data From DUR-928 Phase 1b Trial In NASH And Phase 1 Trial In Hepatic Impairment
6/9/2021 9:13:54 AM
DURECT To Present Additional Clinical Data From DUR-928 Studies In NASH And In Hepatic Impairment
3/4/2021 4:06:58 PM
DURECT Corp. Q4 EPS $0.02 Vs. Loss $0.02 Year Ago
2/4/2021 9:20:01 AM
DURECT Corp. Pricing Of $42.5 Mln Public Offering Of Common Stock
2/2/2021 8:14:05 AM
DURECT Says FDA Has Approved POSIMIR For Infiltration Use
1/25/2021 8:54:23 AM
DURECT Says First Patient Dosed In Phase 2b AHFIRM Study Of DUR-928 In Severe Alcohol-Associated Hepatitis
1/4/2021 8:57:29 AM
DURECT Announces Closing Of LACTEL Absorbable Polymer Product Line Sale To Evonik And Receipt Of $15 Mln